Catherine M Roe1, Anne M Fagan, Elizabeth A Grant, David M Holtzman, John C Morris. 1. From the Knight Alzheimer's Disease Research Center (C.M.R., A.M.F., E.A.G., D.M.H., J.C.M.), Department of Neurology (C.M.R., A.M.F., D.M.H., J.C.M.), Hope Center for Neurological Disorders (A.M.F., D.M.H.), Departments of Pathology and Immunology (J.C.M.), Physical Therapy (J.C.M.), and Occupational Therapy (J.C.M.), and Division of Biostatistics (E.A.G.), Washington University School of Medicine, St. Louis, MO.
Abstract
OBJECTIVES: To test whether CSF Alzheimer disease biomarkers (β-amyloid 42 [Aβ42], tau, phosphorylated tau at threonine 181 [ptau181], tau/Aβ42, and ptau181/Aβ42) predict future decline in noncognitive outcomes among individuals cognitively normal at baseline. METHODS: Longitudinal data from participants (N = 430) who donated CSF within 1 year of a clinical assessment indicating normal cognition and were aged 50 years or older were analyzed. Mixed linear models were used to test whether baseline biomarker values predicted future decline in function (instrumental activities of daily living), weight, behavior, and mood. Clinical Dementia Rating Sum of Boxes and Mini-Mental State Examination scores were also examined. RESULTS: Abnormal levels of each biomarker were related to greater impairment with time in behavior (p < 0.035) and mood (p < 0.012) symptoms, and more difficulties with independent activities of daily living (p < 0.012). However, biomarker levels were unrelated to weight change with time (p > 0.115). As expected, abnormal biomarker values also predicted more rapidly changing Mini-Mental State Examination (p < 0.041) and Clinical Dementia Rating Sum of Boxes (p < 0.001) scores compared with normal values. CONCLUSIONS: CSF biomarkers among cognitively normal individuals are associated with future decline in some, but not all, noncognitive Alzheimer disease symptoms studied. Additional work is needed to determine the extent to which these findings generalize to other samples.
OBJECTIVES: To test whether CSF Alzheimer disease biomarkers (β-amyloid 42 [Aβ42], tau, phosphorylated tau at threonine 181 [ptau181], tau/Aβ42, and ptau181/Aβ42) predict future decline in noncognitive outcomes among individuals cognitively normal at baseline. METHODS: Longitudinal data from participants (N = 430) who donated CSF within 1 year of a clinical assessment indicating normal cognition and were aged 50 years or older were analyzed. Mixed linear models were used to test whether baseline biomarker values predicted future decline in function (instrumental activities of daily living), weight, behavior, and mood. Clinical Dementia Rating Sum of Boxes and Mini-Mental State Examination scores were also examined. RESULTS: Abnormal levels of each biomarker were related to greater impairment with time in behavior (p < 0.035) and mood (p < 0.012) symptoms, and more difficulties with independent activities of daily living (p < 0.012). However, biomarker levels were unrelated to weight change with time (p > 0.115). As expected, abnormal biomarker values also predicted more rapidly changing Mini-Mental State Examination (p < 0.041) and Clinical Dementia Rating Sum of Boxes (p < 0.001) scores compared with normal values. CONCLUSIONS: CSF biomarkers among cognitively normal individuals are associated with future decline in some, but not all, noncognitive Alzheimer disease symptoms studied. Additional work is needed to determine the extent to which these findings generalize to other samples.
Authors: Sebastiaan Engelborghs; Karen Maertens; Ellen Vloeberghs; Tony Aerts; Nore Somers; Peter Mariën; Peter P De Deyn Journal: Neurochem Int Date: 2006-01-24 Impact factor: 3.921
Authors: Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2009-02 Impact factor: 10.422
Authors: Rawan Tarawneh; Gina D'Angelo; Elizabeth Macy; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Anne M Fagan; Denise Head; Mark A Mintun; Jack H Ladenson; Jin-Moo Lee; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2011-08 Impact factor: 10.422
Authors: D I Kaufer; J L Cummings; P Ketchel; V Smith; A MacMillan; T Shelley; O L Lopez; S T DeKosky Journal: J Neuropsychiatry Clin Neurosci Date: 2000 Impact factor: 2.198
Authors: Ozioma C Okonkwo; Michael L Alosco; H Randall Griffith; Michelle M Mielke; Leslie M Shaw; John Q Trojanowski; Geoffrey Tremont Journal: Arch Neurol Date: 2010-06
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182
Authors: Michael A Rapp; Michal Schnaider-Beeri; Dushyant P Purohit; Daniel P Perl; Vahram Haroutunian; Mary Sano Journal: Am J Geriatr Psychiatry Date: 2008-02 Impact factor: 4.105
Authors: Adam P Ingber; Jason Hassenstab; Anne M Fagan; Tammie L S Benzinger; Elizabeth A Grant; David M Holtzman; John C Morris; Catherine M Roe Journal: J Alzheimers Dis Date: 2016 Impact factor: 4.472
Authors: Anja Soldan; Corinne Pettigrew; Qing Cai; Mei-Cheng Wang; Abhay R Moghekar; Richard J O'Brien; Ola A Selnes; Marilyn S Albert Journal: JAMA Neurol Date: 2016-06-01 Impact factor: 18.302
Authors: Ganesh M Babulal; Nupur Ghoshal; Denise Head; Elizabeth K Vernon; David M Holtzman; Tammie L S Benzinger; Anne M Fagan; John C Morris; Catherine M Roe Journal: Am J Geriatr Psychiatry Date: 2016-04-19 Impact factor: 4.105
Authors: Niklas Mattsson; Maria C Carrillo; Robert A Dean; Michael D Devous; Tania Nikolcheva; Pedro Pesini; Hugh Salter; William Z Potter; Reisa S Sperling; Randall J Bateman; Lisa J Bain; Enchi Liu Journal: Alzheimers Dement (Amst) Date: 2015-10-03